• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.66% Nasdaq Up0.88%

    Bristol-Myers Squibb Company (BMY)

    -NYSE
    71.96 Down 0.22(0.30%) May 2, 4:01PM EDT
    ProfileGet Profile for:
    Bristol-Myers Squibb Company
    345 Park Avenue
    New York, NY 10154
    United States - Map
    Phone: 212-546-4000
    Website: http://www.bms.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Drug Manufacturers - Major
    Full Time Employees:25,000

    Business Summary 

    Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers chemically-synthesized drug or small molecule, and biologic in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; immunoscience; cardiovascular; and neuroscience. Its products include Baraclude for the treatment of chronic hepatitis B virus infection; Daklinza and Sunvepra for the treatment of hepatitis C virus infection; Reyataz and Sustiva for the treatment of HIV; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; Erbitux, an IgG1 monoclonal antibody that targets and blocks the epidermal growth factor receptor; Opdivo, a fully human monoclonal antibody for non-small cell lung cancer, renal cell cancer, and melanoma; Sprycel, a multi-targeted tyrosine kinase inhibitor for the treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with metastatic melanoma; Abilify, an antipsychotic agent for adult patients with schizophrenia, bipolar mania disorder, and major depressive disorder; Orencia to treat rheumatoid arthritis; and Eliquis, an oral factor Xa inhibitor targeted at stroke prevention in atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders. Its products pipeline includes Beclabuvir, a non-nucleoside NS5B inhibitor that is in regulatory review for the treatment of HCV; BMS-663068, an investigational compound that is being studied in HIV-1; and Prostvac, a Phase III prostate-specific antigen to treat asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. The company was founded in 1887 and is headquartered in New York, New York.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Bristol-Myers Squibb Company

    Corporate Governance 
    Bristol-Myers Squibb Company’s ISS Governance QuickScore as of May 1, 2016 is 3. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 5; Compensation: 3.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. Giovanni Caforio M.D., 51
    Chief Exec. Officer and Director
    5.20M0.00
    Mr. Charles A. Bancroft , 56
    Chief Financial Officer and Exec. VP
    3.23M0.00
    Dr. Francis M. Cuss MB BChir, FRCP, 61
    Chief Scientific Officer, Exec. VP and Member of Science & Technology Committee
    3.04M4.80M
    Ms. Sandra Leung , 55
    Exec. VP and Gen. Counsel
    2.94M522.00K
    Mr. Murdo Gordon ,
    Head of Worldwide Markets and Sr. VP
    1.84M0.00
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders